fosfomycin disodium · Meitheal · NDA 212271
Contepo
Earliest generic entry, as listed
30 Jan 2039
Blocked by patent: US 11541064, US 12702676. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11541064 | use U-4331 | 30 Jan 2039 |
| US 12702676 | use U-4331 | 30 Jan 2039 |
| US 9345717 | use U-4332 | 27 Oct 2034 |
| US 10086006 | use U-4332 | 12 Oct 2034 |
Exclusivities · 2 unexpired
| GAIN | qualified infectious disease product | 22 Oct 2033 |
| NP | new product | 22 Oct 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212271 · 001 · RLD | powder, intravenous | EQ 6GM BASE/VIAL | 30 Jan 2039 |